Pandey Sulekha, Pandey L K, Saxena A K, Patel Nidhi
Department of Obstetrics & Gynecology, Institute of Medical Sciences, BHU, Varanasi, Uttar Pradesh India ; C-48, Naya Bazar, Najafgarh, New Delhi, 110043 India.
Department of Obstetrics & Gynecology, Institute of Medical Sciences, BHU, Varanasi, Uttar Pradesh India.
J Obstet Gynaecol India. 2016 Oct;66(Suppl 1):383-8. doi: 10.1007/s13224-015-0754-1. Epub 2015 Sep 4.
To investigate the role of p53 gene in cervical carcinogenesis.
A total 50 cases and controls were taken after setting exclusion criteria. Venous blood (3 ml) samples were collected in sterile EDTA sterile vials. Both punch biopsy of cervical growth in cases and biopsy from cervix after hysterectomy in controls were performed. Genomic DNA was extracted from tissue and blood using standard protocol of Miller et al. 1994 using chloroform-phenol method. Gene was amplified using specific forward and reverse primers and p53 gene expressions were studied. The present study of p53 gene regulation analyzed the expression of 279-bp bands on 1.5 agarose gel.
Out of the total 50 samples of cases and controls, we were able to isolate DNA from 38 cases and 28 controls in blood and in 22 cases and 22 controls in tissue. In cases of carcinoma cervix, p53 expression is either downregulated or absent in 71.06 % of cases compared to 50 % of controls in blood and 72.73 % of cases compared to 59.09 % of controls in tissue, but these figures were not statistically significant (p = 0.67 and p = 0.167, respectively). p53 positivity rate was only in 27.78 % of squamous cell cancer and 50 % of adenocarcinoma. Three out of nine patients (33.3 %) with L.N. positive status have p53 gene positivity, whereas 23 % (3 out of 13) with L.N. negative status have p53 gene positivity, which is not significantly associated. In our study, p53 overexpression increases with the various stages of cervical cancer.
In our study, we found that there is the increased frequency of upregulation or overexpression of p53 gene in control in both blood (50 %) and tissue (40.9 %), but this association is statistically nonsignificant. In the present study, there is a lack of relationship between p53 overexpression and prognosis in the cervical cancer patients. However, our study lacked larger sample size which otherwise would have been able to lend support to truly significant findings through much larger combined and comparative datasets.
研究p53基因在宫颈癌发生中的作用。
设定排除标准后选取50例病例及对照。静脉血(3毫升)样本收集于无菌乙二胺四乙酸(EDTA)无菌小瓶中。对病例的宫颈肿物进行穿刺活检,对对照进行子宫切除术后宫颈活检。采用1994年米勒等人的标准方案,通过氯仿 - 苯酚法从组织和血液中提取基因组DNA。使用特异性正向和反向引物扩增基因,并研究p53基因表达。本研究对p53基因调控的分析是在1.5%琼脂糖凝胶上分析279碱基对条带的表达。
在病例和对照的50个样本中,我们能够从38例病例和28例对照的血液中以及22例病例和22例对照的组织中分离出DNA。在宫颈癌病例中,与血液中50%的对照相比,71.06%的病例中p53表达下调或缺失;与组织中59.09%的对照相比,72.73%的病例中p53表达下调或缺失,但这些数据无统计学意义(p值分别为0.67和0.167)。p53阳性率在鳞状细胞癌中仅为27.78%,在腺癌中为50%。9例淋巴结阳性患者中有3例(33.3%)p53基因阳性,而13例淋巴结阴性患者中有23%(3例)p53基因阳性,两者无显著相关性。在我们的研究中,p53过表达随宫颈癌的不同阶段而增加。
在我们的研究中,我们发现对照中血液(50%)和组织(40.9%)中p53基因上调或过表达的频率增加,但这种关联无统计学意义。在本研究中,宫颈癌患者中p53过表达与预后之间缺乏相关性。然而,我们的研究样本量较小,否则通过更大的合并和比较数据集本可以为真正有意义的发现提供支持。